^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OBI-R007

    i
    Other names: OBI-R007
    Associations

    News

    Trials
    Company:
    OBI Pharma
    Drug class:
    Globo H-targeted CAR-T immunotherapy
    Associations

    News

    Trials
    almost3years
    Globo H-targeted CAR T cell cancer immunotherapy (AACR 2023)
    Clinical studies with the Globo H vaccines (OBI-822 and OBI-833) and the humanized anti-Globo H antibody (OBI-888) demonstrating an excellent safety profile...As a result, development of CAR T targeting GH may offer a novel anticancer therapeutic agent.Aim: The aim of this study was to develop a CAR T cell therapy targeted against Globo H (obi-R007) using lentivirus-mediated genetic engineering with a proprietary Globo H-specific antibody... In conclusion, our in vitro and in vivo pharmacology and preliminary toxicology studies support clinical development of Globo H CAR T immunotherapy for patients with cancer.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B)
    |
    OBI-833 • OBI-888 • OBI-R007 • adagloxad simolenin (OBI 822)